Form 4: VolitionRx Executive Gael Forterre Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Chief Commercial Officer Gael Forterre reports stock transactions related to tax obligations on restricted stock units.
Summary
- Gael Forterre, Chief Commercial Officer of VolitionRx Ltd, filed a Form 4 detailing changes in beneficial ownership.
- On May 1, 2025, 3,698 shares of common stock were withheld by VolitionRx to cover tax obligations related to the settlement of 8,944 restricted stock units awarded in lieu of cash compensation at a price of $0.4875.
- Following the transaction, Forterre directly owns 159,006 shares of common stock.
- Forterre also indirectly owns 5,000 shares through his spouse and 32,500 shares through Armorica Partners, LLC, where he is the managing director and sole shareholder.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It reflects routine transactions related to executive compensation and tax obligations.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates activity related to compensation and tax obligations, which is a common occurrence.
Stakeholder Impact
- The transaction has a minimal direct impact on shareholders, as it relates to tax obligations on existing equity awards.
Key Dates
| Date | Description |
|---|---|
| 05/01/2025 | Date of stock transaction (tax withholding). |
| 05/05/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, VolitionRx, VNRX, Gael Forterre, Stock Transaction, Restricted Stock Units, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.